ETH Zurich spin-off EVis Bioscience is developing an RNA delivery platform based on extracellular vesicles. It has raised EUR 740,000 in pre-seed funding through the Capital Cell platform to strengthen its team and preclinical programmes.
- Announced on
- Round
- Pre-seed
- Amount
- EUR 740,000
- Location
- Zurich
- Sector
- Biotech & life sciences
Investors
The investors were not named in the announcement.
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic